These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12105773)

  • 1. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease.
    Cohen AD; Luger SM; Sickles C; Mangan PA; Porter DL; Schuster SJ; Tsai DE; Nasta S; Gewirtz AM; Stadtmauer EA
    Bone Marrow Transplant; 2002 Jul; 30(1):23-8. PubMed ID: 12105773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.
    Arceci RJ; Sande J; Lange B; Shannon K; Franklin J; Hutchinson R; Vik TA; Flowers D; Aplenc R; Berger MS; Sherman ML; Smith FO; Bernstein I; Sievers EL
    Blood; 2005 Aug; 106(4):1183-8. PubMed ID: 15886328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.
    Giles FJ; Kantarjian HM; Kornblau SM; Thomas DA; Garcia-Manero G; Waddelow TA; David CL; Phan AT; Colburn DE; Rashid A; Estey EH
    Cancer; 2001 Jul; 92(2):406-13. PubMed ID: 11466696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia.
    Leopold LH; Berger MS; Feingold J
    Clin Lymphoma; 2002 Mar; 2 Suppl 1():S29-34. PubMed ID: 11970768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.
    Wadleigh M; Richardson PG; Zahrieh D; Lee SJ; Cutler C; Ho V; Alyea EP; Antin JH; Stone RM; Soiffer RJ; DeAngelo DJ
    Blood; 2003 Sep; 102(5):1578-82. PubMed ID: 12738663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
    Stadtmauer EA
    Curr Oncol Rep; 2002 Sep; 4(5):375-80. PubMed ID: 12162910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation.
    Chevallier P; Prebet T; Turlure P; Hunault M; Vigouroux S; Harousseau JL; Blaise D; Ifrah N; Milpied N; Mohty M
    Bone Marrow Transplant; 2010 Jan; 45(1):165-70. PubMed ID: 19584826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia.
    Reinhardt D; Diekamp S; Fleischhack G; Corbacioglu C; Jürgens H; Dworzak M; Kaspers G; Creutzig U; Zwaan CM
    Onkologie; 2004 Jun; 27(3):269-72. PubMed ID: 15249716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.
    McKoy JM; Angelotta C; Bennett CL; Tallman MS; Wadleigh M; Evens AM; Kuzel TM; Trifilio SM; Raisch DW; Kell J; DeAngelo DJ; Giles FJ
    Leuk Res; 2007 May; 31(5):599-604. PubMed ID: 16959316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
    Stadtmauer EA
    Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease.
    Nabhan C; Rundhaugen L; Jatoi M; Riley MB; Boehlke L; Peterson LC; Tallman MS
    Ann Oncol; 2004 Aug; 15(8):1231-6. PubMed ID: 15277263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
    Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
    Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fractionated doses of gemtuzumab ozogamicin combined with 3 + 7 induction chemotherapy as salvage treatment for young patients with acute myeloid leukemia in first relapse.
    Malfuson JV; Konopacki J; Thepenier C; Eddou H; Foissaud V; de Revel T
    Ann Hematol; 2012 Dec; 91(12):1871-7. PubMed ID: 22820971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapeutic advances in neoplastic hematology: target therapy anti-CD33].
    Di Rocco A; Finolezzi E; Anaclerico B; Calabrese E; Levi A; Trasarti S; Tafuri A
    Clin Ter; 2005; 156(4):183-6. PubMed ID: 16342520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probable veno-occlusive disease after treatment with gemtuzumab ozogamicin in a patient with acute myeloid leukemia and a history of liver transplantation for familial hemochromatosis.
    O'Boyle KP; Murigeppa A; Jain D; Dauber L; Dutcher JP; Wiernik PH
    Med Oncol; 2003; 20(4):379-84. PubMed ID: 14716035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.
    Sievers EL; Larson RA; Stadtmauer EA; Estey E; Löwenberg B; Dombret H; Karanes C; Theobald M; Bennett JM; Sherman ML; Berger MS; Eten CB; Loken MR; van Dongen JJ; Bernstein ID; Appelbaum FR;
    J Clin Oncol; 2001 Jul; 19(13):3244-54. PubMed ID: 11432892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?
    Molnár I; Powell BL
    Curr Hematol Malig Rep; 2007 May; 2(2):104-10. PubMed ID: 20425358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
    Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
    BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
    Giles FJ
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):630-40. PubMed ID: 12503209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.